orforglipron

2 articles

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Eli Lilly launched its oral weight-loss drug Foundayo (orforglipron) in the UK, marking the first European availability and offering a lower price point than injectable alternatives while pending EU r

reuters · 2026-08-23 16:07

Eli Lilly Says China Approval for Oral GLP-1 Pill Could Come by 2026

Eli Lilly executives state their oral GLP-1 drug orforglipron may gain China approval between late 2026 and early 2027. Rival Novo Nordisk also plans to seek approval soon as competition grows in the

reuters · 2026-06-23 23:36

Product Info

Name (EN)	Orforglipron
CAS No.	2212020-52-3
Molecular Formula	C48H48F2N10O5
Type	product
Other Names (EN)	1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy